ArticleSurgical case reports2025
Conversion Surgery after Complete Response to Immune Checkpoint Inhibitor-Based Sequential Chemotherapy for Initially Unresectable Perihilar Cholangiocarcinoma: A Case Report.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPerihilar cholangiocarcinoma (PHCC) is often diagnosed at an advanced stage, and surgical resection is frequently precluded due to local progression, distant metastases, or insufficient liver remnant function. Although systemic chemotherapy has recently improved outcomes in unresectable biliary tract cancer, reports of conversion surgery after achieving pathological complete response (pCR) remain extremely rare, thus the role of salvage surgery remains unclear. CASE PRESENTATION: A woman in her 50s presented with abdominal distension and jaundice. Imaging revealed a bile duct stricture below the hepatic duct confluence with a 30-mm pericholedochal lymph node invading the hepatic arteries and portal vein bifurcation. Cytology confirmed adenocarcinoma, and she was diagnosed with unresectable PHCC (Bismuth type II, UICC T4N1M0, stage IIIC). First-line gemcitabine, cisplatin, and S-1 (GCS) chemotherapy was given for 8 courses, resulting in marked lymph node shrinkage, though vascular involvement persisted. Due to adverse events, the regimen was switched to gemcitabine, cisplatin, and durvalumab (GCD) for 7 courses, which maintained disease control. After 13 months of sequential chemotherapy, hepatic functional reserve was adequate, and left portal vein reconstruction with hepatic artery preservation was feasible. Conversion surgery consisting of right hemihepatectomy with portal vein resection/reconstruction and extrahepatic bile duct resection was performed. Pathology showed no residual tumor cells and extensive fibrosis with chronic inflammation, confirming a pCR. The patient has been receiving adjuvant S-1 and remains disease-free 4 months postoperatively.
conclusionsThis case demonstrates that sequential chemotherapy-specifically GCS followed by GCD-can enable conversion surgery and possibly achieve pCR in initially unresectable PHCC. The case highlights the potential of sequential chemotherapy to expand curative options for this otherwise highly lethal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.